En Es
Categories

Industry News


Nova's Stat Profile Prime Plus Blood Gas Analyzer Receives FDA Clearance for POC Use

By HospiMedica International staff writers
20 Apr 2020

Image: Nova's Stat Profile Prime Plus critical care blood gas analyzer (Photo courtesy of Nova Biomedical)Nova Biomedical (Waltham, MA, USA) has secured clearance from the US Food and Drug Administration (FDA) for its Stat Profile Prime Plus critical care blood gas analyzer for point-of-care (POC) use. The clearance allows POC personnel to perform bedside critical care testing with lab-quality results in as little as one minute. Prime Plus incorporates Nova’s maintenance-free sensor technology with individual MicroSensor Cards, calibrator cartridges, and quality control cartridges. This design eliminates sensor and co-oximeter maintenance, improves analyzer uptime, and reduces testing costs.

Prime Plus features maintenance-free sensor technology to provide 19 essential critical care tests including blood gases, electrolytes, metabolites, hematology, and co-oximetry, providing clinicians with a rapid, detailed diagnostic profile, including a comprehensive metabolic panel. The Prime Plus MicroSensor Card™ provides a critical care panel, which includes pH, PCO2, PO2, SO2%, Na, K, Cl, iCa, iMg, glucose, lactate, urea, creatinine, Hct, Hb, O2Hb, COHb, MetHb, and HHb and requires a small 60?l minimum sample volume. Prime Plus features patented, non-lysing whole blood co-oximetry technology, which eliminates corrosive lysing reagents and mechanical complexity while improving instrument reliability and reducing costs.

A unique safety sample port allows for easy docking and hands-free sampling, and the Clot Block™ sample flow path protects sensors from blood clot blockages and related downtime. Prime Plus provides real-time supplemental quality monitoring with automated QC that verifies analyzer accuracy and precision. The on-board assayed liquid controls meet or exceed all current regulatory guidelines and do not require the development of an Individualized Quality Control Plan (IQCP). Supplemental quality monitoring electronically tracks and verifies analytical performance between QC intervals and for each analysis and calibration.






E-mail Print
FaceBook Twitter Google+ Linked in

Nova Biomedical

Nova is a world leader in the development and manufacturing of whole blood, point-of-care and critical care analyzers. Nova’s biosensor technology is incorporated into products ranging from handheld meters for self- and point-of-care testing to critical care whole blood analyzers designed for rapid measurement of over 20 analytes.
Gold member
More info

More articles about Nova Biomedical

25 Jan 2021
Nova Biomedical Adds Sample Retain Collector to BioProfile FLEX2 Cell Culture Analyzer
Nova Biomedical (Waltham, MA, USA) has added a Sample Retain Collector (SRC) for its BioProfile FLEX2 automated cell culture analyzer which measures up to 16 tests including pH, gases, metabolites, osmolality, cell density, and cell viability.
Read More
19 Nov 2020
Nova Biomedical Launches New Laboratory Blood Glucose Reference Analyzer
Nova Biomedical (Waltham, MA, USA) has launched Nova Primary, a rapid, accurate, easy to use, blood glucose laboratory analyzer that fills the need for a new glucose reference analyzer to replace the YSI STAT PLUS 2300 Glucose and L-Lactate analyzer from YSI, Inc., (Yellow Springs, OH, USA).
Read More
20 Apr 2020
Nova's Stat EMS Basic Blood Testing System Launched in CE Mark Countries
Nova Biomedical (Waltham, MA, USA) has launched the Stat EMS Basic blood testing system for ambulance and emergency care in CE mark countries. Stat EMS Basic measures fingerstick capillary lactate, glucose, ketone, hemoglobin, and hematocrit in six to 40 seconds with laboratory-quality results.
Read More
08 Apr 2020
Nova Biomedical Adds PT/INR Test to Allegro Analyzer for POC Testing
Nova Biomedical (Waltham, MA, USA) has added PT/INR testing for its Allegro capillary blood analyzer for point-of-care (POC) testing in primary care settings. With the ability to test for clotting disorders and monitor the effectiveness of blood-thinning medications, the Allegro and its StatStrip-A companion meter provide 18 clinically important tests to help physicians make therapeutic decisions and adjustments at the POC.
Read More
03 Jan 2020
Nova Biomedical Launches New BioProfile FLEX2 On-Line Autosampler
 Nova Biomedical (Waltham, MA, USA) has launched the BioProfile FLEX2 On-Line Autosampler (OLS), a modular system that connects as many as 10 bioreactors to one FLEX2 analyzer for up to three weeks of walkaway, automated sampling, analysis, and feedback control of key cell culture analytes. The FLEX2 measures up to 16 tests, including pH, gases, metabolites, osmolality, cell density, and cell viability.
Read More

Additional news

22 Sep 2021
Thermo Fisher Launches World’s First Fully Integrated Digital PCR (dPCR) System
Thermo Fisher Scientific Inc. (Waltham, MA, USA) has launched the world’s first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results within 90 minutes.
Read More
17 Sep 2021
44th IHF World Hospital Congress Presents Over 60 Plenary Sessions and 200 Renowned Speakers Across Four-Day Event
The 44th World Hospital Congress organized by The International Hospital Federation (Geneva, Switzerland) will bring together more than 200 healthcare experts, leading industry thinkers, and best practice presenters at over 60 sessions around nursing leadership, humanizing technology, COVID-19 vaccination, the next global pandemic, etc.
Read More
17 Sep 2021
Global Digital Polymerase Chain Reaction (dPCR) Market Projected to Reach Close to USD 1.15 Billion by 2028
 The global digital polymerase chain reaction (dPCR) market is projected to grow at a CAGR of more than 9% from over USD 0.50 billion in 2020 to nearly USD 1.15 billion by 2028, driven primarily by rising infectious diseases, technological developments, as well as increased knowledge and acceptance of tailored treatments.
Read More
15 Sep 2021
Certest Offers Sensitive, Useful and Cheap CE-IVD Multiplex Assay for Rapid Diagnosis of Atypical Pneumonia
CerTest Biotec (Zaragoza, Spain) has developed and validated the CE-IVD multiplex assay VIASURE C. pneumoniae, M. pneumoniae & L. pneumophila real time PCR kit for the detection of principal pathogens implicated in atypical pneumoniae.
Read More
15 Sep 2021
Mesa Laboratories to Acquire Molecular Diagnostics Tools Company Agena Bioscience
Mesa Laboratories, Inc. (Lakewood, CO, USA) has entered into a definitive agreement to acquire Agena Bioscience, Inc. (San Diego, CA, USA).
Read More
14 Sep 2021
Zoll Acquires Medical Device and Digital Health Company Itamar Medical
ZOLL Medical Corporation (Chelmsford, MA, USA), an Asahi Kasei company, has signed an agreement to acquire Itamar Medical Ltd. (Caesarea, Israel), a medical device and digital health company focused on the integration of sleep apnea diagnosis into the cardiac patient care pathway.
Read More
13 Sep 2021
Global Blood, Gas and Electrolyte Analyzers Market Projected to Reach Nearly USD 3.50 Billion by 2023
The global blood, gas and electrolyte analyzers market is projected to grow at a CAGR of 8.6% from more than USD 2.10 billion in 2016 to nearly USD 3.50 billion by the end of 2023, driven by rapid developments in the healthcare sector that are resulting in the implementation of technologies to help care providers and patients in treating diseases. For instance, hospitals are implementing technologies like AR and VR that can provide real-time simulation of human body that can help them understand the anomaly of patients. However, the need for blood, gas analyzers to achieve greater accuracy and the requirement of regular maintenance are expected to hinder market growth.
Read More
09 Sep 2021
Stryker Completes Acquisition of Medical Device Company Gauss Surgical
Stryker (Kalamazoo, MI, USA) has completed the acquisition of Gauss Surgical (Menlo Park, CA, USA), a medical device company that has developed Triton, an artificial intelligence-enabled platform for real-time monitoring of blood loss during surgery.
Read More
08 Sep 2021
Global In Vitro Diagnostics (IVD) Quality Control Market Projected to Reach USD 1.4 Billion by 2026
The global in vitro diagnostics (IVD) quality control market is projected to grow at a CAGR of 5.3% from USD 1.1 billion in 2021 to USD 1.4 billion by 2026, thanks to the significant role played by IVD testing in clinical decision-making.
Read More
Copyright © 2000-2021 TradeMed.com. All rights reserved. | Terms And Conditions